Tari Ao Whānui

I te 11 o Hune, i panuitia e Kelun-Biotech kua whakawhiwhia ki te Tohu Whakaora Pakaru (BTD) te putea rongoā TROP2 ADC (佳泰莱) i whakawhanakehia motuhaketia, me te antibody monoclonal PD-L1 tagitanlimab (科泰莱), e te Center for Drug Evaluation (CDE) o te National Med...Pānuihia atu»

I te 29 o Mei, i whakaaetia e te National Medical Products Administration (NMPA) te hokohoko o Zanidatamab, i tukuna mai e BeiGene, hei rongoā mō ngā tūroro e pangia ana e te mate pukupuku o te ara biliary tract (BTC) kāore e taea te tango, kāore hoki e taea te horapa, kua whiwhi kē i te rongoā pūnaha me te whakaatu i te HER2 teitei...Pānuihia atu»

I te 4 o Hune, 2025, ka panuitia e Akeso kua whakaaetia e te National Medical Products Administration (NMPA) te cadonilimab, te paturopi bispecific PD-1/CTLA-4 tuatahi o te kamupene, hei rongoā tuatahi mō te mate pukupuku waha kōpū pumau, pūmau, horapa rānei, me te platinum...Pānuihia atu»

I te 29 o Mei, i whakaaetia e te National Medical Products Administration (NMPA) te HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) hei hokohoko. E tohuhia ana hei rongoā kotahi mō te maimoatanga o ngā tūroro pakeke me te mate pukupuku iti kāore e taea te tango i te rohe kua whanake, i te metastatic rānei ...Pānuihia atu»

I te 21 o Mei, 2025, i panuitia e InnoCare Pharma kua whakaaetia e te China National Medical Products Administration (NMPA) te Minjuvi® (tafasitamab), he paturopi monoclonal kua whakarerekētia ki te Fc, he CD19 cytolytic kua whakarerekētia ki te tangata, me te hono atu ki te lenalidomide, ā, muri iho ko te Minjuvi monotherapy, mō te t...Pānuihia atu»

I te 22 o Mei, 2025, i panuitia e Allist Pharmaceuticals kua whakaaetia mana te whakarewatanga o tana rongoā auaha Airuikai (Glecirasib Citrate Tablets), he aukati KRAS-G12C, e te National Medical Products Administration (NMPA). Mā te whakaaetanga ka taea te whakamahi i a Airuikai mō te maimoatanga...Pānuihia atu»

I te 22 o Mei, 2025, i panuitia e Kelun Bio kua whakaaetia te tono mō tētahi tohu hou mō tana trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, e mōhiotia ana ko SKB264/MK – 2870) (®) e te Center for Drug Evaluation (...Pānuihia atu»

I roto i te pakanga roa ki te mate pukupuku, ka puta tonu mai ngā patu hou hei ārai i te mate pukupuku, e kawe mai ana i te tumanako hou ki ngā tūroro. I roto i te pakanga roa i waenganui i te tangata me te mate pukupuku, kei te puta ake ngā patu hou hei ārai i te mate pukupuku, tētahi i muri i tētahi, e kawe mai ana i te tumanako hou ki ngā tūroro. Hei te mea he pakanga hou e kanapa ana...Pānuihia atu»

I te tau 2021, i hangaia e tētahi tūroro mate pukupuku repeure he merekara hauora, 67 tau te pakeke. Whai muri i te pokanga, ngā rauna maha o te chemotherapy, me te korenga o te rongoā TIL, nā te whakamātautau haumanu o te rongoā pūtau TCR-T i uru atu ia i whakaiti i te horapa o ngā pūkahukahu mā te 72% i roto i ngā marama e 6...Pānuihia atu»

I te 12 o Mei, 2025, ka pānuitia e CARsgen ngā raraunga haumanu tuatahi mō CT0596, he CAR-T allogeneic BCMA-arotahi i whakawhanakehia mā te whakamahi i te tūāpapa THANK-u Plus™. Kei te arotakehia a CT0596 i roto i tētahi rangahau haumanu tūhuratanga wawe mō te myeloma maha kua hoki mai/whakakeke (R/R MM) kua hoki mai/whakakeke rānei...Pānuihia atu»

I te 9 o Mei, 2025, i panuitia e Hansoh Pharmaceutical kua whakaaetia he tohu hou mō Ameile (papa almonertinib mesylate) hei hokohoko. Ko te tohu hou mō te maimoatanga tāpiri o ngā tūroro pakeke e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kua whakahoutia te epidermal growth factor e ngā pukupuku...Pānuihia atu»

I te 1 o Mei, 2025, i panuitia e Hansoh Pharmaceutical kua whakaaetia te werohanga HS-20089 i whakawhanakehia e te Rōpū hei rongoā Breakthrough-Therapy-Tohu e te National Medical Products Administration (NMPA) o Haina, mā...Pānuihia atu»